Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.42 |
| ▸ | SORD | Q00796 | 7/20 | 0.41 |
| ▸ | KIF18A | Q8NI77 | 4/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20745663 | 0.85 | SORD (0.41) | SORDNR1H2AOC3PANK3 | |
| SCHEMBL22320566 | 0.84 | ACACB (0.41) | SORDKIF18AACACBNR1H2ROCK2 | |
| SCHEMBL20745111 | 0.83 | SORD (0.37) | TRPV3SORDKIF18AACACBNR1H2 | |
| SCHEMBL20745960 | 0.83 | ACACB (0.41) | SORDACACBNR1H2ROCK2 | |
| SCHEMBL28059125 | 0.81 | ACHE (0.46) | SORD | |
| SCHEMBL16815392 | 0.80 | PIK3CA (0.51) | SORD | |
| SCHEMBL20745044 | 0.79 | NR1H2 (0.36) | SORDKIF18AACACBNR1H2ROCK2 | |
| SCHEMBL20746289 | 0.78 | PIK3CA (0.50) | SORD | |
| SCHEMBL20745038 | 0.78 | PIK3CA (0.50) | SORD | |
| SCHEMBL16815333 | 0.78 | ACHE (0.50) | SORD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112739343-A | Macrocyclic MCL-1 inhibitors and methods of use | 艾伯维公司 | 2021-04-30 | — | — | CN | disclosed |
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2020-08-13 | — | — | US | disclosed |
| EP-3668504-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | AbbVie Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019035914-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255451-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | TRPV3 4808/4885SORD 4665/4885KIF18A 1490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.